160 related articles for article (PubMed ID: 26211902)
41. Multiple Lipid Nanoparticles (MLN), a New Generation of Lipid Nanoparticles for Drug Delivery Systems: Lamivudine-MLN Experimental Design.
Cavalcanti SMT; Nunes C; Lima SAC; Soares-Sobrinho JL; Reis S
Pharm Res; 2017 Jun; 34(6):1204-1216. PubMed ID: 28315084
[TBL] [Abstract][Full Text] [Related]
42. PEGylated nanostructured lipid carriers (PEG-NLC) as a novel drug delivery system for biochanin A.
Wang L; Luo Q; Lin T; Li R; Zhu T; Zhou K; Ji Z; Song J; Jia B; Zhang C; Chen W; Zhu G
Drug Dev Ind Pharm; 2015; 41(7):1204-12. PubMed ID: 25010850
[TBL] [Abstract][Full Text] [Related]
43. Intracellular interactions of electrostatically mediated layer-by-layer assembled polyelectrolytes based sorafenib nanoparticles in oral cancer cells.
Poojari R; Kini S; Srivastava R; Panda D
Colloids Surf B Biointerfaces; 2016 Jul; 143():131-138. PubMed ID: 26998875
[TBL] [Abstract][Full Text] [Related]
44. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis.
Pastor M; Moreno-Sastre M; Esquisabel A; Sans E; Viñas M; Bachiller D; Asensio VJ; Pozo AD; Gainza E; Pedraz JL
Int J Pharm; 2014 Dec; 477(1-2):485-94. PubMed ID: 25445528
[TBL] [Abstract][Full Text] [Related]
45. Hepatoma-targeting and pH-sensitive nanocarriers based on a novel D-galactopyranose copolymer for efficient drug delivery.
Ding Y; Han J; Tian B; Han J; Zhang J; Zheng H; Han Y; Pei M
Int J Pharm; 2014 Dec; 477(1-2):187-96. PubMed ID: 25455771
[TBL] [Abstract][Full Text] [Related]
46. [Preparation and in vitro characterization of apigemin-loaded nanostructured lipid carriers].
Zhai YJ; Guo CY; Hou JN; Zhang WD; Zhai GX
Zhong Yao Cai; 2011 Jun; 34(6):962-5. PubMed ID: 22017012
[TBL] [Abstract][Full Text] [Related]
47. Oil-enriched, ultra-small nanostructured lipid carriers (usNLC): a novel delivery system based on flip-flop structure.
Keck CM; Baisaeng N; Durand P; Prost M; Meinke MC; Müller RH
Int J Pharm; 2014 Dec; 477(1-2):227-35. PubMed ID: 25455773
[TBL] [Abstract][Full Text] [Related]
48. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC).
Fang JY; Fang CL; Liu CH; Su YH
Eur J Pharm Biopharm; 2008 Oct; 70(2):633-40. PubMed ID: 18577447
[TBL] [Abstract][Full Text] [Related]
49. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability.
Zhuang CY; Li N; Wang M; Zhang XN; Pan WS; Peng JJ; Pan YS; Tang X
Int J Pharm; 2010 Jul; 394(1-2):179-85. PubMed ID: 20471464
[TBL] [Abstract][Full Text] [Related]
50. Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats.
Wang H; Wang H; Yang W; Yu M; Sun S; Xie B
AAPS PharmSciTech; 2018 Feb; 19(2):761-768. PubMed ID: 28983849
[TBL] [Abstract][Full Text] [Related]
51. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery.
Date AA; Vador N; Jagtap A; Nagarsenker MS
Nanotechnology; 2011 Jul; 22(27):275102. PubMed ID: 21606564
[TBL] [Abstract][Full Text] [Related]
52. [Study on preparation of quercetin nanostructured lipid carriers and their physicochemical properties].
Yu L; Yang JR; Liu Y; Zhou T; Kuang YM; Lu SS; Zhang TY; Guo Y
Zhongguo Zhong Yao Za Zhi; 2013 Apr; 38(8):1151-5. PubMed ID: 23944027
[TBL] [Abstract][Full Text] [Related]
53. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery.
Gonzalez-Mira E; Egea MA; Souto EB; Calpena AC; García ML
Nanotechnology; 2011 Jan; 22(4):045101. PubMed ID: 21169662
[TBL] [Abstract][Full Text] [Related]
54. Lipid nanoparticles as carrier for octyl-methoxycinnamate: in vitro percutaneous absorption and photostability studies.
Puglia C; Bonina F; Rizza L; Blasi P; Schoubben A; Perrotta R; Tarico MS; Damiani E
J Pharm Sci; 2012 Jan; 101(1):301-11. PubMed ID: 21905033
[TBL] [Abstract][Full Text] [Related]
55. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.
Fernando J; Malfettone A; Cepeda EB; Vilarrasa-Blasi R; Bertran E; Raimondi G; Fabra À; Alvarez-Barrientos A; Fernández-Salguero P; Fernández-Rodríguez CM; Giannelli G; Sancho P; Fabregat I
Int J Cancer; 2015 Feb; 136(4):E161-72. PubMed ID: 25053293
[TBL] [Abstract][Full Text] [Related]
56. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
[TBL] [Abstract][Full Text] [Related]
57. Preparation of Coenzyme Q10 nanostructured lipid carriers for epidermal targeting with high-pressure microfluidics technique.
Chen S; Liu W; Wan J; Cheng X; Gu C; Zhou H; Chen S; Zhao X; Tang Y; Yang X
Drug Dev Ind Pharm; 2013 Jan; 39(1):20-8. PubMed ID: 23116283
[TBL] [Abstract][Full Text] [Related]
58. A novel method to produce solid lipid nanoparticles using n-butanol as an additional co-surfactant according to the o/w microemulsion quenching technique.
Mojahedian MM; Daneshamouz S; Samani SM; Zargaran A
Chem Phys Lipids; 2013 Sep; 174():32-8. PubMed ID: 23743405
[TBL] [Abstract][Full Text] [Related]
59. Sorafenib tosylate-loaded nanosuspension: preparation, optimization, and
Khanuja HK; Awasthi R; Dureja H
J Chemother; 2024 Jul; 36(4):299-318. PubMed ID: 37881008
[TBL] [Abstract][Full Text] [Related]
60. In vivo studies on the oridonin-loaded nanostructured lipid carriers.
Zheng D; Dai W; Zhang D; Duan C; Jia L; Liu Y; Zhang Q
Drug Deliv; 2012 Aug; 19(6):286-91. PubMed ID: 22928767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
